140 related articles for article (PubMed ID: 32162400)
21. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
[TBL] [Abstract][Full Text] [Related]
22. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
24. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma.
Hicks KA; Leeper HJ; Curran KM
Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074
[TBL] [Abstract][Full Text] [Related]
25. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
Kim C; Matsuyama A; Mutsaers AJ; Woods JP
Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
[TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020).
Merino-Gutierrez V; Borrego JF; Puig J; Hernández A; Clemente-Vicario F
J Small Anim Pract; 2021 Oct; 62(10):881-885. PubMed ID: 34131916
[TBL] [Abstract][Full Text] [Related]
27. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017).
Musser ML; Taikowski KL; Johannes CM; Bergman PJ
BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869
[TBL] [Abstract][Full Text] [Related]
28. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
Remerowski SM; Herrera CL; Donnelly LL
BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
[TBL] [Abstract][Full Text] [Related]
29. Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs.
Hume KR; Rizzo VL; Cawley JR; Balkman CE
J Vet Intern Med; 2018 Jan; 32(1):377-383. PubMed ID: 29193327
[TBL] [Abstract][Full Text] [Related]
30. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
[TBL] [Abstract][Full Text] [Related]
31. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
32. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
33. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
Mitchell L; Thamm DH; Biller BJ
J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
[TBL] [Abstract][Full Text] [Related]
34. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.
Heaton CM; Fernandes AFA; Jark PC; Pan X
J Vet Intern Med; 2020 Mar; 34(2):873-881. PubMed ID: 31977135
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report.
Fuertes-Recuero M; Vázquez-Fernández E; Lizasoain-Sánz G; Arroba-Alonso A; Sánchez-López A; Martínez-de-Merlo E; Suárez-Redondo M; Ortiz-Diez G
Vet Res Commun; 2024 Jun; 48(3):1921-1927. PubMed ID: 38453822
[TBL] [Abstract][Full Text] [Related]
37. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
Harper A; Blackwood L
J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
[TBL] [Abstract][Full Text] [Related]
38. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
39. Investigation of thyroid function in dogs treated with the tyrosine kinase inhibitor toceranib.
Harper A; Blackwood L; Mason S
Vet Comp Oncol; 2020 Sep; 18(3):433-437. PubMed ID: 31498949
[TBL] [Abstract][Full Text] [Related]
40. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
